NATIONAL BUREAU OF ECONOMIC RESEARCH
NATIONAL BUREAU OF ECONOMIC RESEARCH

The Value of Pharmacogenomic Information

John A. Graves, Shawn Garbett, Zilu Zhou, Josh Peterson

NBER Working Paper No. 24134
Issued in December 2017
NBER Program(s):Health Care

Pharmacogenomics, or the application of genetic testing to guide drug selection and/or dosing, is often cited as integral to the vision of how precision medicine can be integrated into routine clinical practice. Yet despite a growing base of scientific discovery on genetic variation that predicts drug response, reimbursement for genetic testing among health systems and payers remains uneven. In large measure this is because the cascading impacts of genetic testing on individual and provider incentives and behavior, as well as downstream health care spending and outcomes, remain poorly understood. In this study, we couple evidence from a real-world implementation of pharmacogenomic testing with a discrete event simulation model. We use this framework to evaluate the cost-effectiveness of various genetic testing strategies. We find that the cost-effectiveness of multiplexed genetic testing (e.g., whole genome sequencing) hinges on the ability of a health system to ensure that dense genotypic information is routinely utilized by physicians. Moreover, while much attention has been paid to lowering the cost of genetic tests, we demonstrate that in practice, other scientific and behavioral factors, focused on certain high-yield drug-gene pairs, are key to implementing precision medicine in ways that maximize its value.

download in pdf format
   (704 K)

email paper

The NBER Bulletin on Aging and Health provides summaries of publications like this.  You can sign up to receive the NBER Bulletin on Aging and Health by email.

Machine-readable bibliographic record - MARC, RIS, BibTeX

Document Object Identifier (DOI): 10.3386/w24134

Forthcoming: The Value of Pharmacogenomic Information, John A. Graves, Zilu Zhou, Shawn Garbett, Josh F. Peterson. in Economic Dimensions of Personalized and Precision Medicine, Berndt, Goldman, and Rowe. 2018

Users who downloaded this paper also downloaded* these:
Einav and Finkelstein w24055 Moral Hazard in Health Insurance: What We Know and How We Know It
Howard, Hockenberry, and David w24054 Personalized Medicine When Physicians Induce Demand
Hackmann w24133 Incentivizing Better Quality of Care: The Role of Medicaid and Competition in the Nursing Home Industry
Foster and Gehrke w24041 Consumption Risk and Human Capital Accumulation in India
De Nardi, French, and Benson w17688 Consumption and the Great Recession
 
Publications
Activities
Meetings
NBER Videos
Themes
Data
People
About

National Bureau of Economic Research, 1050 Massachusetts Ave., Cambridge, MA 02138; 617-868-3900; email: info@nber.org

Contact Us